Last reviewed · How we verify
LPV/RTV pellets and AZT/3TC or ABC/3TC
LPV/RTV pellets and AZT/3TC or ABC/3TC is a Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Drugs for Neglected Diseases. It is currently in Phase 3 development for HIV-1 infection in pediatric patients (pellet formulation).
This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps.
This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps. Used for HIV-1 infection in pediatric patients (pellet formulation).
At a glance
| Generic name | LPV/RTV pellets and AZT/3TC or ABC/3TC |
|---|---|
| Sponsor | Drugs for Neglected Diseases |
| Drug class | Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Lopinavir/ritonavir (LPV/RTV) inhibits HIV protease, preventing the maturation of viral particles and reducing infectious virions. The nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) block reverse transcriptase, preventing conversion of viral RNA to DNA. Together, these agents provide synergistic suppression of HIV replication through complementary mechanisms. The pellet formulation is designed for pediatric administration.
Approved indications
- HIV-1 infection in pediatric patients (pellet formulation)
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities
- Hepatotoxicity
- Pancreatitis
- Peripheral neuropathy (AZT-related)
- Anemia (AZT-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LPV/RTV pellets and AZT/3TC or ABC/3TC CI brief — competitive landscape report
- LPV/RTV pellets and AZT/3TC or ABC/3TC updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI
Frequently asked questions about LPV/RTV pellets and AZT/3TC or ABC/3TC
What is LPV/RTV pellets and AZT/3TC or ABC/3TC?
How does LPV/RTV pellets and AZT/3TC or ABC/3TC work?
What is LPV/RTV pellets and AZT/3TC or ABC/3TC used for?
Who makes LPV/RTV pellets and AZT/3TC or ABC/3TC?
What drug class is LPV/RTV pellets and AZT/3TC or ABC/3TC in?
What development phase is LPV/RTV pellets and AZT/3TC or ABC/3TC in?
What are the side effects of LPV/RTV pellets and AZT/3TC or ABC/3TC?
What does LPV/RTV pellets and AZT/3TC or ABC/3TC target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Drugs for Neglected Diseases — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in pediatric patients (pellet formulation)
- Compare: LPV/RTV pellets and AZT/3TC or ABC/3TC vs similar drugs
- Pricing: LPV/RTV pellets and AZT/3TC or ABC/3TC cost, discount & access